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Abstract. The new outbreak of coronavirus from december 
2019 has brought attention to an old viral enemy and has 
raised concerns as to the ability of current protection 
measures and the healthcare system to handle such a threat. It 
has been known since the 1960s that coronaviruses can cause 
respiratory infections in humans; however, their epidemic 
potential was understood only during the past two decades. 
In the present review, we address current knowledge on coro-
naviruses from a short history to epidemiology, pathogenesis, 
clinical manifestation of the disease, as well as treatment and 
prevention strategies. Although a great amount of research 
and efforts have been made worldwide to prevent further 
outbreaks of coronavirus-associated disease, the spread and 
lethality of the 2019 outbreak (cOVId-19) is proving to be 
higher than previous epidemics on account of international 
travel density and immune naivety of the population. Only 
strong, joint and coordinated efforts of worldwide healthcare 
systems, researchers, and pharmaceutical companies and 
receptive national leaders will succeed in suppressing an 
outbreak of this scale.
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1. Introduction
Respiratory infections are common in the cold seasons world-
wide, and consequently considered trivial and mild. Affected 
individuals rarely consult medical professionals, instead 
treating themselves with symptomatic medications. droplet 
and aerosol transmission further facilitates rapid dissemi-
nation to numerous individuals at once, which amplifies 
socioeconomic impact even with minimal increases to fatality 
rate, particularly among patients with comorbidities.
The latest and contemporary outbreak of a respiratory 
pathogen, namely severe acute respiratory syndrome coro-
navirus 2 (SARS-coV-2) responsible for coronavirus disease 
(cOVId-19), has brought to attention a hidden threat from 
an old enemy. This is the third major coronavirus outbreak 
over the past 20 years that has had substantial socioeconomic 
impact, but the first in the 21st century to affect countries 
across all continents except Antarctica. The general panic and 
insecurity expressed across all sociopolitical and economic 
tiers has dramatically disrupted day-to-day life, international 
travel and trade. Notwithstanding severe lifestyle disrup-
tions, depression-associated disease has been reported due to 
extreme measures of isolation.
Here we emphasize current knowledge regarding coro-
naviruses from a short history to epidemiology, diagnosis, 
pathogenesis, clinical manifestation, as well as treatment 
and prevention strategies. Forward lessons informing future 
strategies to improve surveillance and prevent recurrence are 
highlighted.
2. A brief overview of coronavirus infections in human 
history
SARS-coV-2 belongs to the Orthocoronavirinae subfamily, 
family Coronaviridae, order Nidovirales (1). It comprises of 
four subtypes, α- and β-coronaviruses that can infect humans, 
and gamma- and delta-coronaviruses, which are found only 
in animals. It is a zoonotic virus that can be transmitted from 
animals to humans and, once adapted to do so, between humans 
via airborne droplets and aerosols (2). The most involved 
carrier animal species for human infections is the bat (3), 
though animal reservoirs extend to cattle, pigs, turkeys, camels, 
mice, dogs, cats, ferrets and mink (4,5). The first coronavirus 
infections were reported in 1960 as a cause for the common 
cold. Since then, until 2002, four subtypes of coronaviruses 
were reported to infect humans, two α coronaviruses - 229E 
and NL63 and 2 β coronaviruses - Oc43 and HKU1, which 
routinely produce noncomplicated infections of the upper 
and/or lower respiratory tract (3). Then, 2002 marked a key 
moment in our understanding of coronavirus-induced disease 
with the emergence of the first lethal severe acute respira-
tory syndrome (SARS)-causing coronavirus. Similarly to 
SARS-coV-2, the original SARS-coV emerged in Guangdong 
Province in china, spreading through human transmission 
chains to infect at least 8,096 individuals in 29 countries and 
succumb 774 patients (6). In 2012, a novel β-coronavirus that 
had not previously been observed in humans was detected 
for the first time in a patient in Saudi Arabia. Since then, the 
new coronavirus, which causes Middle Eastern Respiratory 
Syndrome and is now known as MERS-coV, has infected 
>2,494 individuals across 27 countries and led to the death 
of at least 858 individuals as of November 2019, through 
a series of emergences and re-emergences from camelid 
hosts (7). On december 8, 2019, in Wuhan, Hubei Province, 
China, the first case was reported of a new coronavirus that 
produces pneumonia. Since then, the new virus first named 
2019-ncoV and subsequently renamed SAS-coV-2 was identi-
fied as a member of the β-coronavirus subtype, spread rapidly 
via human-to-human transmission. At the time of authoring 
(March 23, 2020), over 317,298 cases have been recorded 
worldwide across 166 countries, with over 13,642 deaths 
attributed to the virus (8) (Fig. 1).
3. Epidemiology of coronavirus infections
The emergence of virulence strains of coronavirus over the 
past 20 years has increased the interest of scientists regarding 
coronavirus strain variability, distribution, and the ability 
to be transmitted between animals to humans and further 
from humans-to-humans. The strains have slightly different 
distributions across sex, age and other demographic attributes. 
For example, whilst SARS-coV-2 affects males more than 
females with substantial age-associated mortality increases 
in frail elderly subjects, the four societally non-disruptive 
coronaviruses affect more females and children between 
5 and 14 years (9).
In contrast, SARS-coV-1 affected more females, and rela-
tively young people with the median age of SARS infected 
patients in Guangzhou province, china at 28.6 years) (10), and 
mortality rate at ~12% in people over 65 years (11). In compar-
ison, the MERS coronavirus was more frequently detected 
among males and middle-aged adults aged 50-59 years (12). 
Emerging data from hospitalized cOVId-19 cases in Wuhan 
(Hubei province, china) indicate males (68%) and middle-age 
adults in the age group of 50-59 years to be predominantly 
affected, with a prevalence under 10% in people aged 
<39 years. Among these cases, 51% had chronic diseases such 
as cardiovascular and cerebrovascular diseases (40%), endo-
crine system disease (13%), digestive system disease (11%), 
respiratory system disease (1%), malignant tumor (1%), and 
nervous system disease (1%) (13). Likewise, data from Italy 
as of 15/3/20 indicate a median age of 64 years with middle 
aged (51-70 years old) and elderly (75.7%), predominantly 
male (59.8%) patients experiencing mild (46.1%) to severe 
(24.9%) disease and the burden of mortality (70-79 years old: 
case fatality ratio 12.5%; 80-89 years old: 19.7%; >90 years 
old: 22.7%) (14). Whilst the older population demographics of 
Italy is believed to drive the higher case fatality ratio differ-
ences (7.9%) vs. china (4.0%) (15), the Italian healthcare 
system is experiencing increased requirement for intensive 
care unit (IcU) admission (~10% of cases) (16). Anecdotal 
reports from frontline clinicians in the principally affected 
regions in Italy indicate all IcU beds dedicated to cOVId-19 
and patient admission to IcU/mechanic ventilation restricted 
to age groups with a higher likelihood of survival. Of note, 
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these reports indicate 20% of IcU cases to involve individuals 
under the age of 65 and as young as 20 years of age. The reader 
is strongly advised to consider carefully the territory‑specific 
diversity of case severity definition as well as the diagnostic 
triage/definition criteria before making direct epidemiological 
comparisons.
One additional aspect complicating case epidemiological 
oversight pertains to the highly mutagenic nature of corona-
viruses, which is common across RNA viruses, and has led 
to inappropriate comparative evolution interpretations and 
even the incorrect assertion of mild and sever cOVId-19 
arising from separate strains of SARS-coV-2. By comparing 
genomes of sequenced cOVId-19 strains, it was shown that 
synonymous mutations in spike genes between cOVId-19 and 
rat or bat coronaviruses (RaTG13 and Bat-SL-coVZc45) were 
quite different. The ratio of nucleotide substitutions to amino 
acid substitutions was 9.07 in cOVId-19 compared with 
RaTG13, which was significantly higher than the 3.91 ratio 
from cOVId-19 to Bat-SL-coVZc45 (17). Additionally, there 
were numerous concerns that cOVId-19 was an engineered 
bioweapon, hypotheses fed by speculation that sequences from 
cOVId-19 were identical to those in HIV. Alignments showed 
that they are not present in any other coronavirus strains, but 
show identity/similarity with sequences in HIV-1 gp120 and 
Gag, the former being also a cellular receptor recognition 
protein (18). considering that these inserts appear in hyper-
variable regions of the protein and are as short as 6 residues in 
length, it is most probable that they arose naturally: as a conse-
quence the article describing these similarities was recently 
withdrawn from publication. To date, no evidence supports 
that SARS-coV-2 is man-made: cOVId-19 closely resembles 
two other coronaviruses that have triggered outbreaks in 
recent decades, SARS-coV-1 (79% sequence identity) and 
MERS-coV (51.8% identity) (19), and all three viruses are 
most likely to have originated in bats (17,20): SARS-coV-2 
has a 96% sequence identity with a recently sequenced bat 
coronavirus recovered from the wild by random sampling (21).
4. The transmission model
A major question regarding coronavirus epidemiology is 
‘Why does the bat of all animals play such a central role in 
coronavirus epidemiology?’. Studies in bats have identified 
viruses originating in this species, as the potential vector to 
human infections. Additionally, as bats live in colonies, they 
present a high risk of transmitting the viruses horizontally 
(intra-species) which contributes to the vertical (cross-species) 
spreading ability. This hypothesis is strongly favored by data 
on another high socioeconomic impact bat-derived virus, the 
Ebola virus, which was shown to efficiently infect both bat and 
Figure 1. History of coronavirus infections in humans.
Table I. The comparative clinical evolution of coronavirus infections.
coronavirus strain Incubation period death period Symptoms
SARS coV 4-10 days 20-25 days Fever, dry cough, myalgia, dyspnea, headache, sore throat, sputum
   production, rhinorrhea watery diarrhea confusion, poor appetite
MERS coV  5-6 days 11-13 days Myalgia, fever, chills, malaise associated with confusion, cough,
   shortness of breath, dyspnea pneumonia
cOVId-19  3-7 days 17-24 days Fever, cough, dyspnea, muscle ache confusion, headache, sore throat,
   rhinorrhea, chest pain, diarrhea, nausea, vomiting, anosmia, dysgeusia
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human cells (22) and to date remains the favored hypothesis for 
index case infection in the 2014-16 West African Ebolavirus 
disease outbreak.
Additional evidence of bat to human indirect transmission 
comes from the cOVId-19's Spike protein and AcE2 receptor 
interactions (23). Indeed, the two highly pathogenic strains of 
coronaviruses ‑ SARS‑CoV and MERS‑CoV were identified 
both in bat species and in animals involved in transmission 
to humans (20). It is interesting to note that the first highly 
pathogenic strain of coronavirus, SARS-coV-1, has a low 
genetic similarity with other known coronaviruses (39% with 
bovine coronavirus and 46% with porcine epidemic diarrhea 
virus) (24). Recently, three comparison studies were made with 
coronavirus strains from pangolins. The first (February 18, 
2020) compared the sequences of cOVId-19 with the coro-
naviruses in illegally trafficked pangolins to show a sequence 
similarity between 85.5 and 92.4% (25), with the subsequent 
papers (February 20, 2020), reporting sequence similarities 
with pangolin coronaviruses at 90.23% (26) and 91.02% (27), 
respectively. However, the α-coronavirus strains that cause 
human disease were also originally identified in bats (28); it 
is therefore not surprising that cOVId-19 shares 96% genetic 
similarity (whole genome level) with a coronavirus isolated 
from chinese bat species (21). Another important question is 
‘Why china?’ china is the third-largest country by surface 
area worldwide but the most populated country. Its varied 
land characteristics and diverse climate range supports huge 
biodiversity, which contributes to enabling transmission of 
viruses between animal populations. Principally, however, 
co-habitation of animals and humans in close proximity, and 
gastronomic customs involving the consumption of a variety 
of exotic animals, including wild fauna such as bats, increases 
the chance of vertical transmission throughout the food supply 
chain. Officially, live‑bird markets have been closed; however, 
black-market vendors run illegal slaughterhouses, that are 
crowded places with poor ventilation, where a number of 
species are hoarded together: These create ideal conditions 
for the spreading of the virus through airborne droplets of 
blood and other secretions, or shared cages, trade tools, and 
utensils, allowing for an ‘amplification’ of vertical transmis-
sion risk. The prevalence of such culinary and wild animal 
handling practices in Southern china have been causally 
linked to both the 2002 SARS-coV-1 outbreak starting from 
a market in Shenzen (Guangdong, china) (29) and the entry 
Figure 2. The transmission model of coronaviruses.
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of SARS-coV-2 into the human population. Of the original 
41 cases presenting with pneumonia of unknown origin, two 
thirds had links to Huanan Seafood Wholesale Market that 
also sold live animals (30).
Such a species barrier bridge has been also documented 
with filovirus disease outbreaks in Africa, wherein high risk 
infectious agents are routinely detected in bushmeat markets 
and the associated human population both by PcR and 
immunoprecipitation methods (31). As with china, human and 
animal close contact and often co-habitation remains common 
in rural African areas with practically no barriers to wild 
environments (e.g., tropical forests). Such exposure data have 
fed debates on the role of so-called ‘herd immunity’ through 
natural exposure to emerging tropical, or perhaps rural, 
zoonoses. It is noteworthy that, comparable risks have been 
documented with viruses not typically associated with highly 
biodiverse geographies or the consumption of wild meat. For 
example, the 2012 outbreak of MERS-coV in the Middle East 
and the Arab peninsula specifically, was shown to involve both 
local and international city dwellers with no previous exposure 
to the natural camelid host that continues to be in close contact 
with rural populations (Fig. 2) (32,33). The direct impact on 
individual health of zoonoses, and indirect impact on health-
care systems as evidenced through the cOVId-19 outbreak, 
underscore how increasingly urban population organisation 
even among developing nations amplifies the risk of onward 
human transmission, despite past exposure and indeed immu-
nity in settings with blurred wild-human habitat barriers.
5. Pathogenesis of coronavirus infection
The genome of coronaviruses contains genes for the 4 struc-
tural proteins: Envelope (E), membrane (M), nucleocapsid (N) 
and spike (S). coronavirus virions are lipid bilayer-enveloped 
particles variable in size (80-160 nm), characterized by multiple 
20-nm spike-like extensions on the surface in the form of 
‘corolla’ or ‘flower petals’. At the virion core, a nucleocapsid 
with icosahedral symmetry contains an electron-dense layer 
with a center that is clear. Its genomic nucleic acid consists 
of is single-stranded positive RNA which requires a negative 
RNA replication cycle intermediate that generates subgenomic 
protein coding RNAs as well as genomic RNA for virion 
assembly. The core also features accessory proteins that differ 
considerably between various types of coronaviruses.
The lipidic envelope features the trimerically-organised 
Type I transmembrane spike glycoproteins which consist of 
the ectodomain subunits S1 and S2 protruding externally, a 
transmembrane anchor, and a tail extending towards the viral 
core (34). cell attachment involves the S1 subunit interacting 
with host cell surface receptors driving endocytosis and, after 
membrane fusion with the involvement of subunit S2 (35), 
release of the virion core into the cytosolic milieu. The glyco-
proteins of coronaviruses mediate attachment, fusion, and 
entry in the host cells, but different parts of those glycoproteins 
are involved in each of these processes. These class I viral 
membrane-fusion proteins undergo structural rearrangements 
that produce fusion between the viral and cellular membranes. 
Figure 3. Pathogenesis of coronavirus infections.
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Glycoprotein conformational changes and cathepsin L prote-
olysis within endosomes are also involved in the pathogenesis 
of coronavirus (Fig. 3). Thus, whilst cleavage of S protein is 
required to expose the hydrophobic fusion peptide, it seems that 
receptor interaction is required for the cleavage to occur (36). 
Historically, immunotherapies and many exploratory small 
molecule treatments have targeted such host-pathogen interac-
tions to disrupt infection. However, experience across multiple 
virus strains indicates such monotherapy to be inefficient due 
to mutational escape.
Accessory proteins play a definitive role in infectivity, 
however, their functions are not yet fully understood. It is 
speculated that some proteins play important roles in coun-
tering the immune response; thus, viruses that lack these 
have a lower infectivity. For example, SARS-coV-1 has two 
accessory proteins, 3a and 3b, that play potential roles in the 
virulence of this strain (37). On the other hand, sometimes a 
complete infectious particle can be assembled without spike 
proteins, indicating that accessory proteins can substitute 
these (38). Therefore, there is a potential risk that a vaccine 
targeting structural proteins alone, such as the spike protein, 
might be inefficient, driving evolutionary escape of the virus, 
either through target protein mutation, or by favouring virions 
utilizing other accessory proteins for attachment. A some-
what more viral escape-proof approach involves targeting 
of the receptor-binding domain (RBd) which is a conserved 
domain of S protein (39). Notably, other respiratory viruses 
that efficiently cross species barriers (e.g., influenza) require 
close monitoring and annual adjustment of epitope targeting 
to minimize spread and impact.
The primary receptor used by coronaviruses to enter 
into target cells is the angiotensin-converting-enzyme II 
(AcE2) receptor (21,40), although some strains also use other 
alternative receptors, such as cd209L, for which they have 
a lower affinity (41). Whilst there is no evidence in pre‑ or 
post-publication literature currently that SARS-coV-2 also 
utilizes cd209L for cell entry this potential attachment 
mechanism cannot be excluded until experimental data thereto 
are produced. Likewise, other, as yet unidentified receptors, 
facilitate coronavirus cellular entry in the absence of AcE2 
in hepatocytes and some enterocytes (42). SARS-coV-2 in 
particular, also appears to use the SARS-coV receptor AcE2 
to enter cells. Although the spike protein between SARS-coV-1 
and -2 vary in sequence, Xu et al (43) suggested that the Spike 
protein binding affinity for ACE2 is conserved as the 3D struc-
ture of the receptor binding domain is identical with that of 
SARS-coV-1, which would translates to equal infectivity. The 
analysis of protein-protein interaction using bioinformatics 
showed that SARS nucleocapsidal proteins bind to human 
cyclophilin A (hcypA) and this binding was demonstrated 
by surface plasmon resonance (SPR) technology. The 3d 
modelling detected the probable binding sites and allowed 
deduction of important interaction between residue pairs (44). 
Wan and colleagues observed that several amino acids in 
the receptor-binding motif of SARS-coV-2 allow binding to 
human AcE2, even though with suboptimal strength (45). A 
recent study demonstrated that a mutation in the Spike protein 
(N501T) of SARS‑CoV‑2 enhanced the affinity for ACE2 (45).
AcE2 is highly expressed in the respiratory tract, 
particularly in epithelial cells of the bronchi, alveoli (both 
type I and II cells), trachea and bronchial serous glands, as 
well as in macrophages and alveolar monocytes. Notably, the 
expression in the lung cells is much higher than in trachea (46). 
In line with the expression profile of ACE2, viral genome load 
has been consistently reported to be both more elevated in the 
lower than in the upper respiratory tract, with lower respira-
tory specimens being additionally less prone to false negative 
results (47,48). AcE2 is also diffusely located on other cells, 
such as mucosal cells of the intestines, endothelial cells of 
veins and arteries including heart cells, epithelial cells of the 
renal tubules, epithelial cells of the kidneys, immune cells 
and cerebral neuronal cells, which may also be susceptible to 
coronavirus infections. The observation of cOVId-19 patient 
demise on account of severe heart failure brought about by 
SARS-coV-2 infection and the higher risk among patients with 
previous cardiovascular and hypertensive disease has driven 
multiple hypotheses regarding potential direct mechanisms of 
viral action on the circulatory system. Thus, AcE2 expression 
can be increased as a result of using drugs such as AcE inhibi-
tors and angiotensin II type-I receptor blockers (ARBs). Indeed, 
it was shown that expression of AcE2 is increased in diabetes 
patients (another high risk cOVId-19 group) treated with AcE 
inhibitors and hypertension patients, treated with ARBs. AcE2 
expression can also be increased by thiazolidinediones and 
ibuprofen. Therefore, in these categories of patients, the risk 
of infection with cOVId-19 is proposed to be higher (49). Yet, 
whilst the NL63 coronavirus strain binds to the same AcE2 
receptor as SARS-coV-2, it produces only upper respiratory 
tract disease. This indicates that there are other unknown 
factors, apart from the presence of receptors that influence the 
susceptibility of cells to coronavirus infection. Insights into the 
differentiation factors influencing coronavirus strain‑specific 
outcomes come from recent data on host co-factors mediating 
SARS-coV-2 fusion. Thus, SARS-coV-2 uses the serine 
protease TMPRSS2 for S protein priming; camostat mesylate, 
an inhibitor of TMPRSS2, blocked cOVId-19 infection 
of lung cells, but inhibition was more substantial when the 
endosomal cysteine protease cathepsin B/L (catB/L) was 
also inhibited e.g., with E-64d (40). These results point to a 
complex interplay of host factors in the endosome with the 
spike protein in mediating virion fusion. It is thus speculated 
that in infected cells furin-mediated precleavage at the S1/S2 
site can promote TMPRSS2-dependent entry, as in the case of 
MERS-coV (40). MERS-coV however is an exception to the 
SARS coronavirus set, as it uses at hedipeptidyl peptidase 4 
(dPP-4) surface antigen as a receptor, and not AcE2. The 
relative expression of these endosomal factors and similarly 
active proteins across cell types, as well as alternative recep-
tors that mediate cellular attachment require urgent scrutiny 
to understand cell type tropism, and, more crucially, extra-
pulmonary reservoirs and sites of replication. Some of these 
extrapulmonary reservoirs have been suggested by cT scans 
showing shadows and interstitial changes in tissues separate 
to the lungs (50), which require molecular and cellular studies 
to confirm direct involvement in virus replication as opposed 
to pathological findings secondary to SARS‑CoV‑2 infection.
After coronaviruses infect primary cells, the mature 
virions can be released and infect other target cells (51). 
Infective viral particles can be found in sweat, stool, urine and 
respiratory secretions from patients with other coronaviruses, 
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with viable SARS-coV-2 so far documented in respiratory 
droplets, saliva, mechanically generated aerosols, and faeces. 
After excretion environmental contamination can be substan-
tial (fomites) presenting what is currently believed to be the 
primary mode of human-to-human transmission for up to 
7 days after surface deposition of the virus. The development 
of atypical pneumonia with rapid respiratory deterioration and 
failure determined by coronavirus infection is associated with 
increased levels of activated pro‑inflammatory chemokines 
and cytokines (52). Thus, it has been proposed that Vitamin d 
plays a role in the modulation of the immune response to 
infectious agents, based on laboratory findings and obser-
vational studies. However, randomized clinical trials have 
returned inconclusive, often controversial results. Therefore, 
it has been suggested that cholecalciferol at elevated doses 
might be useful for the prevention and therapy of infection 
with cOVId-19 (53,54).
In the pathogeny of coronavirus infection, an important 
role is played by the amplitude of host immunity; for example, 
canonical interferon levels terminate protein synthesis or 
even induce cell death. However, the intensity of the immune 
response can vary, depending on other comorbidities of the 
patient, explaining the role of these in the evolution of the 
disease. Indeed, the majority of deaths have occurred among 
individuals with comorbidities (55). In a nationwide study 
from china, 2.1% of patients with cOVId-19 had cancer, 
however no patient had liver transplantation or inflamma-
tory bowel disease, 7.4% of the patients had diabetes and 
15% hypertension (56). The death rate is expected to be higher 
in immunocompromised patients, however this is not estab-
lished to date. On the other hand, it seems that the exacerbated 
immune reaction in cOVId-19 infection is the one that leads 
to the greatest pulmonary and systemic damage.
MERS-coV has a lower infectivity compared to 
SARS-coV-2; thus, an intense and prolonged exposure is 
necessary in order for the virus to enter the lungs. MERS-coV 
uses dPP-4 as a cell receptor (57). dPP-4 is expressed in a 
wide variety of epithelial cells with localization in the alveoli, 
kidneys, liver, small intestine, prostate and activated leukocytes 
that determine the higher tropism of MERS-coV compared to 
other coronaviruses (58).
The genome of SARS-coV-2 was sequenced during the 
early stages of the outbreak, enabling the ultrafast develop-
ment of point-of-care tests based on RT-PcR for the new 
cOVId-19 infection within 2 weeks of its discovery (45), in 
line with past predictions of rapid response (59) (https://doi.
org/10.1039/c7Sc03281A). To date, however, these are avail-
able only in kit format for benchtop real time PcR systems 
requiring substantial manual processing (5-8 h minimal 
data turnaround). Emergency use authorization (EUA) for 
the use of these/similar assays in a handful of the numerous 
regulator-approved point-of-care integrated extraction-ampli-
fication systems (e.g., BioFire, GeneXpert, etc.) was obtained 
only on March 22, 2020, an unacceptable 3 months into the 
outbreak. consequently, despite the tremendous need for mass 
screening and isolation of infected cases, sample processing 
bottlenecks have forced most health authorities and govern-
ments worldwide to restrict testing only to clinically complex, 
hospitalized cases. conversely, experience from countries 
with early outbreak experience such as Korea, Singapore, 
Hong Kong, Taiwan, Italy, and indeed china shows that mass 
testing, case isolation and contact tracing can reduce human 
transmission even to zero. Indeed, presently the risk to these 
countries appears restricted to new case introduction from 
abroad, justifying measures seeking to halt international travel.
diagnostic process notwithstanding, a major drawback 
lies with the diagnostic sensitivity of preferred as opposed to 
available samples. Thus, data from the chinese centres for 
disease control and Prevention, as well as clinical centres at 
the epicenter of the outbreak, have reinforced World Health 
Organisation technical diagnostic guidelines (60) that require 
a lower respiratory sample as well as an upper respiratory 
sample to rule out SARS-coV-19 as the causal agent of 
viral pneumonia and cOVId-19-like disease. The simplest 
upper respiratory sample is presented in the form of an oral 
and/or nasal swab (or combination of both, given the handful 
of reported nasal swab negatives in the presence of oral swab 
positives). Lower respiratory specimens are difficult to obtain 
as they require either intubated patients (tracheal aspirates), 
or anesthesia (bronchoalveolar lavage, bronchial brushings). 
Notwithstanding risk of injury to the patient, these invasive 
procedures create infectious aerosol generation risks and are 
contraindicated. The only suitable surrogate sample is lung 
sputum, but only if this is naturally available, to minimize 
aerosol generation risk. Unfortunately, the chinese experience 
has been that <30% of cOVId-19 suspected cases generate 
sputum, thereby restricting testing to oral or nasal swabs. 
These, however, have a reported false negative rate of between 
10-37% (47,48), with oral swab false negative rates on account 
of low analytical sensitivity reaching up to 68%. These 
statistics point underscore the impact of sampling process 
variability beyond anatomical differences - one healthcare 
professionals' swabbing technique may differ vastly to another- 
and emphasize the need for standardizing/automating the 
sampling process to increase diagnostic test reliability, even 
for respiratory samples. A significant additional complicating 
factor is the limited understanding of sample viral load across 
the exposure-symptomatic-convalescence continuum, onset 
of shedding, and disparity between genome copy detected by 
RT-PcR vs infectious virion copy number, which collectively 
amplify the well-established issues around operator error in 
sampling methods. Of interest, early data suggest viral shed-
ding may indeed start as early as one week ahead of symptoms 
and transmission may peak up to 3 days before symptoms (61). 
The data, if accepted and validated in separate studies, will 
compound the impact of transmission risk attributed to 
asymptomatic or subclinical individuals and will emphasize 
the need for more aggressive contact tracing. Testing even onto 
random mass population screening will be needed to arrest 
transmission, as anecdotal evidence suggests from a single 
town in Italy where the combination of lockdown, contact 
tracing and testing eliminated new cases whilst transmission 
remained rampant elsewhere in the country (62).
On the other hand, there is particular importance attributed 
by a number of Western governments to serological assays that 
monitor the production of antibody responses to pathogens. 
At first glance these tests are exceedingly appealing due to 
their lower cost (50-100x) and time-to-results (30-48x) as 
compared to RT-qPcR in a diagnostic lab, or indeed when 
using automated point of care RT-qPcR systems (20x lower 
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cost and 6-12x faster). In addition, antibody tests can offer a 
clear answer as to the spread of exposure that may involve 
asymptomatic or low-grade respiratory disease, supporting 
so called ‘herd immunity’. However, evidence from multiple 
Asian countries and Italy show transmission containment was 
achieved and can be achieved using RT-qPcR which docu-
ments infectious cases: antibody responses do not initiate until 
at least a week after the onset of symptoms, meaning that the 
deployment of antibody tests for mass screening will have an 
enhanced risk of false negatives as compared to oronasal swab 
RT-qPcR by missing pre-symptomatic, asymptomatic, and 
newly symptomatic cases. Whilst the research and academic 
value in understanding asymptomatic spread is undisputed, 
the magnitude of the socioeconomic damage by cOVId-19 in 
redirecting resources away from confirmation of active infec-
tion in mildly symptomatic cases and asymptomatic contacts 
onto exposure numbers, is likely to extend transmission long 
beyond the period of a few weeks documented in china and 
Korea into months, extending the impact onto healthcare 
systems. Furthermore, such an extension of spread risks the 
development of cycles of infection and socioeconomic damage 
with the re-introduction of new index cases within country 
regions and into countries free of the disease. The increasing 
risk of virus evolution, and its establishment as a seasonal, 
endemic respiratory disease agent, crucially, does not take 
into account how immunity to other coronaviruses appears 
to be short-lived: we simply do not know yet if cOVId-19 
convalescence will protect from re-infection, and if it does, 
for how long.
6. Clinical manifestations of coronavirus‑associated 
diseases
The predominant symptoms of SARS-coV-1 are respiratory 
in nature, associated with fever and diarrhea. clinical mani-
festations among patients are diverse, from mild-moderate 
to severe-life threatening symptoms. The virus has a mean 
incubation period of 4.6 days (63), however in the majority of 
cases, symptoms appear after 10 days (64). In severe cases, the 
median time from the appearance of symptoms until artificial 
ventilation is 11 days, and 23.7 days until the patient's death (65). 
The clinical manifestations are similar to flu‑like symptoms, 
such as fever, a dry cough, myalgia, dyspnea, headache, sore 
throat, sputum production, rhinorrhea (66,67). In 40-70% of 
cases, watery diarrhea appears within 1 week after the first 
manifestations (42). In the elderly, the symptoms can also be 
associated with confusion, a poor appetite and a decrease in 
general well-being. In is noteworthy that the symptomatology 
in children below 12 years is mild; no mortality has been 
registered among children and teenagers. Asymptomatic cases 
are reported to be rare (63,68). Increased levels of c-reactive 
protein, lymphopenia, thrombocytopenia, and increased levels 
of lactate dehydrogenase have been observed in laboratory 
tests. The infection manifests in two different stages, with the 
first-week characterized by flu-like symptoms that improve 
even if the viral loads persist, and a recurrent period during the 
second week in which respiratory failure can appear and more 
than 20% of patients may require mechanic ventilation (69). 
The respiratory system is the main affected area in the human 
body where the infection determines the appearance of diffuse 
alveolar damage, squamous metaplasia, giant‑cell infiltrates 
and increased macrophage levels in the interstitium and the 
alveoli (46).
Unlike SARS-coV-1, Middle East Respiratory Syndrome 
coronavirus (MERS-coV) has a wide variety of clinical mani-
festations from asymptomatic to severe respiratory symptoms. 
The mean incubation period is 5-6 days (70-73). In severe 
cases, death can occur within 11-13 days after the onset of 
the disease (70,73). The clinical manifestations are similar 
to flu‑like symptoms, such as general myalgia, fever, chills, 
malaise associated with confusion, pulmonary symptoms, 
such as cough, shortness of breath, dyspnea and pneumonia. 
Extra-pulmonary clinical manifestations include abdominal 
disorders, nausea, diarrhea, vomiting, acute renal failure and 
neurological complications (74). The severity of the disease is 
associated with an increasing age, and with individuals with 
comorbidities, such as diabetes mellitus, renal and pulmonary 
diseases. death can occur after the development of acute 
respiratory distress syndrome (ARdS), multiorgan failure or 
septic shock (7). The neurological complications of the infec-
tion with MERS-coV are associated with the in vitro ability 
of the virus to invade the central nervous system (75), although 
it was not detected in the cSF. Among the neurological mani-
festations, confusion has been reported in 25.7% and seizures 
in 8.6% of cases (76). Severe neurological complications 
are encephalitis, stroke, polyneuropathy, acute disseminated 
encephalomyelitis, Guillain Barré syndrome and Bickerstaff's 
encephalitis. Usually, the neurological complications appear at 
a delayed time point from the respiratory symptoms, namely 
2-3 weeks from the onset of the clinical manifestation of the 
disease and can be underdiagnosed (74,77-79). children are 
rarely affected (74). In laboratory tests, thrombocytopenia, 
lymphopenia, neutrophilia, leucocytosis, reduced renal 
functions and increased inflammatory markers have been 
observed. Similar to SARS-coV-1, the pathogenesis has not 
yet been fully elucidated. Viral-mediated lung damage is 
characterized by diffuse alveolar damage. The virus has been 
determined in multinucleated epithelial cells, pneumocytes 
and bronchial submucosal glands. Apart from the respiratory 
system, the virus has also been identified in the epithelial cells 
of the proximal renal tubules (58). Acute tubular sclerosis and 
tubulointerstitial nephritis have been observed in renal biop-
sies collected from persons infected with MERS-coV (80).
The latest high clinical burden coronavirus, SARS-coV-2, 
presents a wide variety of clinical manifestations which are not 
yet fully characterized (81,82). The virus has a mean incubation 
period of 3-7 days, and no more than 14 days (30) - although 
anecdotal reports likely related to poor contact tracing have 
suggested potentially up to 24 days of incubation. Outside 
Hubei province, the median incubation period has been 
estimated to be 5.1 days (95% cI: 4.5 to 5.8), with 97.% of 
infected subjects developing symptoms within 11.5 days of 
infection (83). In a retrospective study on 99 patients that 
have confirmed COVID‑19 pneumonia treated in an infec-
tious diseases hospital in Wuhan, china, it was shown that the 
main clinical manifestations were flu‑like symptoms, such as 
fever and cough (83 and 81% of the cases), shortness of breath 
(31% of cases), muscle ache (11% of cases), and less frequently 
confusion (9%), headache (8%), sore throat, rhinorrhea, and 
chest pain. In less than 2% of patients, extra-pulmonary symp-
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toms and diarrhea, nausea and vomiting were also observed. 
As complications, ARdS was reported in 17% of cases 
followed by acute respiratory injury (8%), septic shock (4%), 
acute renal injury (3%), and ventilator-associated pneumonia 
(1%). death occurred in 11% of participants in the study 
determined by multiple organ failure. The main finding in 
laboratory tests was lymphopenia. The severity of the disease 
was associated with co-infections, smoking history, hyperten-
sion and age (13). Another retrospective study on 137 patients 
infected with cOVId-19 revealed the same pattern of clinical 
manifestations with fever, cough and muscle pain, and less 
frequently diarrhea, headache and even heart palpitations 
in some cases (50). Lymphopenia was observed in 72.3% of 
cases associated with normal or decreased white blood cell 
counts (50). The lung is the main organ affected. In the imaging 
examination by computer tomography or X-ray, lesions were 
identified in multiple lung lobes presented as patchy/punctate 
ground-glass opacities (GGO), patchy consolidation, irregular 
solid nodules and fibrous stripes (50,84‑86). Studies that have 
investigated the pulmonary pattern of cOVId-19 pneumonia 
have demonstrated that the disease progresses rapidly, and cT 
re‑examination after 3‑14 days has revealed significant changes 
in lung structure. The single GGO observed in the early stages 
can increase significantly in short‑term re‑examination. The 
same has also occurred with fibrous stripes observed in the 
early stages that consolidate in short-term re-examination. In 
some cases, the irregular solid nodules observed in the early 
stages increased and merged in short-term re-examination. 
Short-term repeated imaging scans should be carried out in 
patients with cOVId-19 pneumonia for monitoring the evolu-
tion and for specific management of the patient as the disease 
can rapidly progress or indeed resolve (86,87). The peak of 
lung abnormalities was reached on day 10 following the onset 
of symptoms, followed by a decrease in symptomatology (87).
It was documented that in one third of the severely ill 
patients, death occurs because the cOVId-19 coronavirus 
produce acute myocardial injury and damage to the cardiovas-
cular system in general, that further degrade the state of these 
already very ill patients (88).
7. Treatment of coronavirus‑associated diseases
The treatment for all types of coronaviruses is mainly 
supportive, as no specific treatment has been discovered to 
date. For the treatment of SARS-coV-1, apart from supportive 
measures, several therapeutic schemes have been implemented, 
with varying success rates such as antiviral therapy with riba-
virin (89), protease inhibitors - lopinavir and ritonavir, alone 
or associated with ribavirin (67,90), interferon-alfacon-1 (91), 
systemic corticosteroids (89,92), and convalescent plasma for 
passive immunotherapy (93). Apart from convalescent plasma, 
none of these treatments have exhibited significant benefits 
compared to the side-effects produced.
For MERS-coV infections, taking as an example the 
early SARS-coV-1 epidemic, supportive care was primarily 
used, and in some instances broad-spectrum antibacterials, 
antivirals such as ribavirin alone or in combination with 
interferon-2α2b (94,95) and antifungals have been used to 
prevent the co-infection with other opportunistic patho-
gens (96,97). Mycophenolic acid is another drug that exhibited 
efficacy in monotherapy on a small number of patients; however 
further studies are required to confirm these effects (98,99).
In the case of the new cOVId-19-associated pneumonia, 
treatment also focuses on supportive care measures and symp-
tomatic treatment. Following the example of SARS-coV-1 
treatment, the administration of systemic corticosteroids was 
attempted, although this did not exhibit any benefits. In the 
case of patients with severe evolution, immunoglobulin G was 
administered (50). The application of early respiratory support 
improved the prognosis and the recovery of the patients (50). 
In a 54-year-old Korean man infected with SARS-coV-2, 
the administration of the combination lopinavir/ritonavir 
from day 10 of illness determined the decrease in viral load 
till no detectable levels (100). The question of whether the 
decrease in viral load was associated with the natural course 
of the healing process or with antiviral treatment or both, is 
being currently investigated in order to confirm the efficacy of 
antiviral treatment for COVID‑19. The efficacy of remdesivir 
(Gilead Sciences), a nucleotide analog, in inhibiting in vitro 
and in vivo SARS-coV-1, MERS-coV and bat coV strains 
that are capable to replicate in human airway epithelial cells 
render it a good choice for testing on newly affected cOVId-19 
patients (85,101-103). Taking into consideration that cOVId-19 
binds to human AcE2 in order to penetrate human cells and to 
induce severe pneumonia, the renin-angiotensin system, AcEI 
(angiotensin-converting enzyme inhibitors) and AT1R (angio-
tensin II type-I receptor) inhibitors have been suggested to 
modify individual susceptibility to COVID‑19 by influencing 
SARS-cov-2 virulence. However, further studies are needed 
to confirm the mechanisms involved (including the role of high 
AcE2 expression) and to consider possible changes in adminis-
tration and dosage of antihypertensive drugs (46,49,104). Thus 
far, the Professional Association for Hypertension Therapy, USA, 
has warned against changes in hypertensive drugs following 
concerns about a possible increased susceptibility to cOVId-19 
(https://ish-world.com/news/a/A-statement-from-the-Interna-
tional-Society-of-Hypertension-on-cOVId-19/). Interest has 
arisen also on the ‘old’, off-patent antimalarial drug chloroquine 
and its less toxic hydroxychloroquine analog, both of which 
are quinine derivatives (cinchoca tree bark, South America). 
Preliminary support from observations of potential inhibitory 
activity against SARS-coV-2 (105,106), clearly needs to be 
confirmed through randomized controlled trials. There are 
also ongoing trials using monoclonal antibodies. One of them 
is tocilizumab, an anti-IL6 antibody, currently in phase III 
clinical trials, with commercial name Actemra produced by 
Roche (107). Sarilumab, a drug used in rheumatoid arthritis is 
about to enter clinical trials for cOVId-19 infection, according 
to Regeneron Pharmaceuticals and Sanofi, respectively (108).
In order to facilitate cOVId-19 virus replication, certain 
in vivo conditions, such as the pH value, the temperature, 
humidity, and the sufficiency of oxygen supply should be 
ensured. consequently, in order to hinder the reproduction 
procedures of the virus, it would be expedient to disturb the 
environment of the virus, by interfering with the temperature or 
the pH values or both. SARS-coV-2 has been speculated to be 
a seasonal virus, in which case a hindrance of the rapid spread 
that characterizes it at ambient temperatures over 25˚‑30˚ 
celsius would be observed. Unfortunately, the sup-tropical/arid 
environments favored by SARS-coV-1 and MERS-coV, as 
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well as the comparatively higher temperatures in Israel, Egypt, 
the Arab peninsula and now sub-Saharan Africa compared 
to Hubei province indicate that temperature probably does 
not affect cOVId-19 replication. Likewise, the ambient 
humidity levels thought to impact aerosol and droplet suspen-
sion time/travel distance, and by extension virus transmission, 
do not seem to affect onward transmission chains across 
geographical regions. Alteration of the pH value inside the 
human body within tolerable levels however is achievable; such 
an intervention would not only suppress replication of the virus, 
but also may have - although possibly weak - virucidal effect. 
A pH value change with no negative impact on the health of the 
patient could be achieved by administering a drug that would 
lead to urine acidosis and endocellular alkalosis. This drug 
could be a simple small molecule with hydrophobic weak base 
properties, which would accumulate in lysosomes after having 
crossed both plasma and lysosomal membranes by diffusion. 
Perhaps such a medicine may express both a therapeutic and 
a prophylactic effect by increasing the environmental barriers 
to effective virus attachment in early endosomal pathways, and 
preventing spike proteolysis required for capsid release and 
cell membrane fusion within lysosomes, in line with cathepsin 
protease-targeted therapies. Given the success of combination 
therapy strategies in other antiviral diseases centered on virus 
fusion and/or replication, promoting endocellular alkalosis 
during antiviral drug therapy (e.g., replication inhibitors) could 
amplify antiviral effect and thereby contribute to the reduction 
of the treatment period (109-113).
8. Prevention strategies
Although since 2004, the World Health Organization 
issued guidelines for the prevention of re-emergence of 
new coronavirus virulent strains (114), implementation has 
evidently been inadequate. Key recommendations include: 
the availability of the early detection of infected individuals 
to prevent the spread of emergent and re-emergent infection, 
particularly to prevent international spread; the development 
of contingency plans by each country for the management 
and detection of coronavirus, individualized by the risks that 
exist locally; preparing global and assisting national risk 
assessments; updating new discoveries; assisting countries 
in their efforts to improve protection against infections; 
assessing the availability of all necessary resources in the 
case of an outbreak; and, supporting the international scien-
tific collaboration for SARS study. Unfortunately, all of these 
strategies could not prevent the current outbreak, and after 
17 years, the medical, scientific and governmental structures 
have demonstrated that they are not adequately prepared 
to effectively contain highly pathogenic viruses. The main 
measures that should be taken for preventing the dissemina-
tion of pathogens in the general population are associated 
with infection control measures both in healthcare facilities 
and in the community. contact tracing and quarantine or 
the isolation of those suspected of infection along with the 
education of the population has proven essential in preventing 
community transmission of the viruses both in developing 
nations (West African and democratic Republic of congo 
Ebola virus outbreaks), developed nations (e.g., Hong Kong, 
South Korea SARS and MERS outbreaks), and now practi-
cally all G20 nations. The lack of local implementation of 
what are demonstrably effective measures, as learned since 
the SARS-coV-1 outbreak due to scientific chauvinism 
over healthcare standards between East and West, popula-
tion anthropology between Africa and Europe in terms of 
communication strategy and behaviour, or indeed local vs 
international experience between e.g., the UK and Italy with 
emerging threats is lamentable. Going forward, the identifica-
tion of natural reservoirs and intermediate hosts for existing 
and future risks as identifiable through random sampling and 
monitoring (21) will become essential in preventing future 
zoonotic virus outbreaks. Unfortunately, these alarms were 
raised repeatedly over the past two decades with minimal 
heed: perhaps the damage brought by cOVId-19 onto global 
economy and healthcare systems will transform the field of 
tropical emergent disease.
A good example of positive action are the actions of 
currently more than 40 teams developing vaccines against 
SARS-coV-2 infection (115); interest is largely spurred by the 
unprecedented success and rapid development of Ebolavirus 
vaccines during the West African outbreak. cOVId-19 
vaccines can be based on the viral RNA or derivatives: 
Examples include Innovio and Moderna in USA, as well as 
cureVac (Germany), and another team at Imperial college in 
London. RNA and dNA vaccines have the advantage of being 
quick to develop and high likelihood of safety, though no RNA 
vaccine or therapeutic currently enjoys regulatory approval. 
The Institute Pasteur in France is working on a traditional 
cOVId-19 vaccine based on a SARS vaccine. canSino 
Biologics developed a recombinant coronavirus vaccine incor-
porating adenovirus type 5 vector (Ad5). To date clinical trials 
have been initiated by Moderna Therapeutics and cansino 
Biologics (115) with further trials shortly anticipated in the 
UK and other European countries.
A sobering note, however, is that despite the ample amounts 
of research performed on coronaviruses over the past 20 years, 
particularly following the SARS-coV-1 outbreak, no vaccine 
is unfortunately yet available for either SARS-coV-1 or 
MERS, although some potential vaccines have reached as far 
as phase I clinical trials (116-118). Some of the strategies used 
for vaccines are eliciting neutralizing-antibody for S proteins 
and T-cell responses (119) which seem to be jointly required 
for convalescence, rather than simply neutralizing antibody 
titers. The quest for protective immunity to coronavirus is but 
nascent, and virology offers a plethora of high socioeconomic 
impact, high prevalence RNA viruses for whom decades of 
vaccine research have yet to deliver success.
9. Conclusions
The Guangdong region of china was considered a high-risk 
area for a coronavirus outbreak after the SARS-coV-1 
epidemic in 2002. Nevertheless, although a large amount of 
research and efforts have been made worldwide to prevent 
further outbreaks, a coronavirus outbreak occurred again 
in 2019. Unfortunately, healthcare systems locally, nationally, 
and now internationally have again been overcome, as with 
the other two major coronavirus outbreaks. The evidence 
from cOVId-19 is clear that highly aggressive measures 
are necessary to break the transmission chain in the regions 
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at risk - practically most countries globally at the time of 
authoring. Unfortunately, there is no specific prevention 
strategy against the new coronavirus, and its pandemic 
status restrict the global community to two options: effective 
measures for the immediate prevention of respiratory infections 
with predictable and measurable consequences, or ambitions 
of ‘herd’ or vaccine‑derived immunity at a non‑specific time 
in the future. We can only hope that after this third significant 
outbreak, sufficient experience has been gained; a joint 
effort of the worldwide health authorities will be needed in 
extinguishing the current epidemic. It can only be trusted that 
this experience will re-emphasize the need for prevention and 
readiness and for further studies to limit the transmission of 
animal viruses to humans and mitigation should it arise again 
in the future.
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